advertisementsupported bya nasal spray version drug ketamine shown promise even properties still well benedict careyof million american adults live many gain little benefit available whether drugs talk represent perhaps greatest unmet need food drug administration approved prescription treatment intended help drug derived old widely used move heralds shift prozac era antidepressant newly approved called nasal spray developed janssen pharmaceuticals branch johnson marketed name contains active portion ketamine whose antidepressant properties well understood goodness something different mechanism action previous erick former reviewer associate professor psychiatry oregon health science skeptical world like lucy holding football charlie time hopes football gets pulled generic anesthetic already increasingly available hundreds clinics around country provide course intravenous studies suggest help often causes hallucinogenic sensations popular club special cost treatments typically generic anesthetic approved esketamine likely would covered many insurance side though similar generic thought less recommended course newly approved drug twice four boosters along one commonly used oral approval requires doses taken office patients monitored least two experience entered patients drive day like potential drugs induce psychotic episodes people high risk safety monitoring require doctors find space treated could present logistical psychiatrists cost course treatment experts give company foothold billion global antidepressant drugs science times page sign science times approval esketamine marks approach treating serious mood experts prozac similar drugs enhance activity brain messengers mildly take weeks months effects many patients provide little relief compounds several others developed work within hours effective people considered meaning benefited exciting todd associate professor psychiatry university maryland school drugs work rapidly treat severe gould involved janssen study identified ketamine breakdown could developed another experts long experience treating depression encouraged effectiveness previous class antidepressants prozac paxil vastly exaggerated came results esketamine paid carried trial patients started antidepressant given course esketamine treatment one monthlong esketamine performed better statistically reducing scores depression scale compared points two others drug statistically outperform placebo required drug succeed two trials agency loosened criteria opting instead study relapse people well janssen reported subjects compared percent subjects received placebo subjects given diagnosis previously failed multiple courses drug nothing steven professor psychiatry behavior sciences vanderbilt drug effective way rapid response people treatment use could question need answered well esketamine performs comparison intravenous adjunct professor english asked name omitted protect lived much life deep tried course generic ketamine local typically entails given couple treatments remember really tripping textures much part infusion provided third noticed satisfying underlying hard thing still felt somehow like something gelled within husband noticed glen founder medical director ny ketamine clinic downtown treated intravenous generic clients received variety including well common medications else infusions quickly reduced symptoms teenagers young seemed less effective people data janssen presented likewise suggested esketamine less effective people aged barely better placebo developed five decades ago safer alternative anesthetic used operating battlefield pediatric world health organization listed ketamine one essential medicines since interest turned potential combat government scientist named phil skolnick argued targeting glutamate pathways primary brain processes could produce antidepressant team researchers yale university connecticut mental health led robert reported doses ketamine provided quick relief seven people field took team national institute mental health led carlos zarate reported people received drug intravenously reported despair lifted within seems remarkable drug seems help domains like suicidal inability feel pleasure chief experimental therapeutics pathophysiology seems broad many areas apparent ability ketamine blunt suicidal thinking particularly janssen pursuing indication jails psychiatry suicide acute risk people drug could save many doctors one knows whether compounds effective generic anesthetic whether hallucinatory fact integral antidepressant need zarate earlier version article misstated cost treatment correct cost carey science reporter times since written three cognitive science science mysteries middle advertisement 